ESC Congress 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
29 August 2017
BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro* and Xience** drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving